ALNY•benzinga•May 19, 2025 at 07:54 AM

Reported Saturday, Alnylam's Vutrisiran Reduces All-Cause And Cardiovascular Mortality By Over 30% In ATTR-CM Patients, New 42-Month HELIOS-B Data Show

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 19, 2025 by benzinga